VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
PLSE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
PLSEPulse Biosciences, Inc.
$53.02$3.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PLSE logo

Pulse Biosciences, Inc.

PLSE
NASDAQ · Medical Instruments
$53.02
At close - Oct 23, 4:00 PM EDT - USD
Market Cap$3.67B
P/E-49.1x
52W High$58.90
Volume452.06K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Nascent Revenue Emergence Amid Persistent Cash Burn

Pulse Biosciences has transitioned from zero revenue to $434K in 2026Q2, marking a pivotal inflection, yet operating losses have widened to $25.3M per quarter, with R&D consuming 67% of costs. The company holds a $101.6M cash buffer (up 288% from 2024Q2) provi...

GrowthAccelerating
ProfitabilityWeak
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

PLSE price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-292% Peers

P/E is 292% below peer median

03

Market leadership

RS 97 · Leader

High momentum (Outperforming 97% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystConfirmed earnings · Nov 5

Market performance

Price History →

Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PLSE+295.97%
S&P 500 (^GSPC)+11.24%
1-Year Return
PLSE+204.71%
S&P 500 (^GSPC)+13.13%
3-Year Return
PLSE+1238.89%
S&P 500 (^GSPC)+83.02%
5-Year Return
PLSE+145.12%
S&P 500 (^GSPC)+73.40%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-49.1x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-49.1x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.06-98.0%
Base (Fair)$1.27-97.6%
Bull$1.06-98.0%
$1.06 Bear$1.27 Base$1.06 Bull
Current Market Price: $53.02
Trades at a 4074.8% premium to Base DCF ($1.27)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$350K
Net income
-$73M-35.8% YoY
Free cash flow
-$54M-49.3% YoY
Operating margin
-21982.6%
ROIC (TTM)-876.1%
Avg ROIC 5Y-
ROE (TTM)-74.4%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (82%)
Revenue Beat Rate2/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 6, 2026
-$0.36-16.1%
vs -$0.31
$434,000-13.2%
vs $500,000
Q2 2026
May 4, 2026
-$0.27+15.6%
vs -$0.32
$400,000+60.0%
vs $250,000
Q1 2026
Feb 19, 2026
-$0.26+1.9%
vs -$0.27
$264,000+76.0%
vs $150,000
Q4 2025
Nov 5, 2025
-$0.29+6.5%
vs -$0.31
$86,000-82.8%
vs $500,000
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Defense World·4d ago
Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Review

Pulse Biosciences (NASDAQ: PLSE - Get Free Report) and Varex Imaging (NASDAQ: VREX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Valuation and Earnings This table compares Pulse Biosciences

GuruFocus·Oct 14, 2026
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™

Business Wire·Oct 14, 2026
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to.

Business Wire·Oct 9, 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appr.

Filtered for Pulse Biosciences, Inc.More Headlines
04

Compare before deciding

Benchmark PLSE against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Pulse Biosciences, Inc. (PLSE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PLSE logoPLSEPulse Biosciences, Inc.Current
$53.02$3.67B-49.09—-20794.57%-74.45%—
INVA logoINVAInnoviva, Inc.
$20.66$1.52B6.2618.52%80.56%30.03%—
NVCR logoNVCRNovocure Ltd
$14.68$1.7B-12.038.28%-21.25%-44%—
ATEC logoATECAlphatec Holdings, Inc.
$11.11$1.71B-11.5724.95%-13.5%-818.99%—
ANAB logoANABAnaptysBio, Inc.
$48.73$1.44B-105.93157.01%82.37%2515.23%—
INMD logoINMDInMode Ltd.
$13.97$803.01M9.77-6.16%20.69%11.8%—

Compare PLSE vs Peers

Pulse Biosciences, Inc. (PLSE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for PLSE.

Scale Benchmark

vs ABT

Larger-name benchmark to compare PLSE against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, NVCR, ATEC, ANAB

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PLSE SEC Filings & Documents

Pulse Biosciences, Inc. (PLSE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

Jul 29, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 19, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

Aug 6, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 5, 2025·SEC

Get notified when PLSE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PLSE Frequently Asked Questions

Pulse Biosciences, Inc. (PLSE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Pulse Biosciences, Inc.'s revenue?

Pulse Biosciences, Inc. (PLSE) reported $1.2M in revenue for fiscal year 2025.

Is PLSE profitable?

Pulse Biosciences, Inc. (PLSE) reported a net loss of $80.1M for fiscal year 2025.

Dividend & Returns
What is PLSE's return on equity?

Pulse Biosciences, Inc. (PLSE) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.

What is Pulse Biosciences, Inc.'s free cash flow?

Pulse Biosciences, Inc. (PLSE) had negative free cash flow of $76.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PLSE back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →